Shared Facilities

Clinical Pharmacology Analytical Core

cpac model

The Clinical Pharmacology Analytical Core (CPAC) is available to assist Indiana University Melvin and Bren Simon Cancer Center (IUSCC) investigators as well as external partners with pre-clinical and clinical pharmacokinetics in support of their research projects and scientific goals.

CPAC has been in existence since September 2004, primarily working with clinical investigators to provide detailed information on drug interactions and pharmacokinetics.

As a result of the identified need for pre-clinical pharmacokinetic and drug metabolism measurements earlier in the drug discovery process (via ITRAC experimental design mapping), CPAC began to expand its capabilities to include discovery pharmacokinetics and preliminary determination of drug metabolism.

The process of rational drug design should be based upon a strong foundation of biology, chemistry, in vivo pharmacology, and pharmacokinetics. Relevant pharmacokinetic and metabolism studies should be conducted in small animal models or in vitro systems before first drug administration in humans. This allows for the iterative process of implementing structural changes in the drug molecule to optimize the activity of the drug and its pharmacological and pharmacokinetic properties prior to moving to the more regulated and expensive clinical phase of drug development. For these reasons, CPAC is now interacting closely with another IUSCC-shared resource, the In Vivo Therapeutics (IVT) Core, to coordinate these efforts.

Over the past year, the CPAC and IVT Core have worked together to generate data allowing principal investigators to better evaluate molecules being developed within the IUSCC that show promise as novel cancer drugs.

Pharmacokinetic and metabolism data provide important information to guide drug design and treatment in pre-clinical drug discovery (bench) as well as in clinical drug development and treatment (bedside). Using state-of-the art technology, CPAC supports the development of safe and more efficacious drug treatment for IUSCC investigators.